

## **ASX ANNOUNCEMENT**

**9 June 2023**

### **Tranche 1 Placement Completion**

---

**IDT Australia Limited** (ASX: IDT) (**Company**) is pleased to announce that further to its ASX announcement dated 5 June 2023, Tranche 1 of the Placement to raise \$5.0 million (before costs) has been completed. 60,938,678 new fully paid ordinary shares (**New Shares**) were issued at a price of \$0.065 per New Share to sophisticated and professional investors.

36,563,207 New Shares were issued utilising the Company's 15% placement capacity under ASX Listing Rule 7.1. The remaining 24,375,471 New Shares were issued utilising the Company's additional 10% placement capacity under ASX Listing Rule 7.1A.

Tranche 2 of the Placement, which includes an issue of 15,984,398 New Shares at an issue price of \$0.065, will be the subject of approval by shareholders at a General Meeting to be held in July 2023.

End

Authorised by the Board of Directors of IDT Australia Limited.

**For investor and media enquiries, please contact:**

Brendon Lau

E: [brendon@vantagepointpartners.com.au](mailto:brendon@vantagepointpartners.com.au)

M: +61 409 341 613

**About IDT**

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.